Overweight and obesity: The pathogenesis of cardiometabolic risk

Després, 2006, Abdominal obesity: The most prevalent cause of the metabolic syndrome and related cardiometabolic risk, Eur Heart J Suppl., 8, B4, 10.1093/eurheartj/sul002 2006, Health, United States, 2006 With Chartbook on Trends in the Health of Americans. Hyattsville, Md 2006, Obesity and overweight, Fact Sheet No. 311 Colditz, 1995, Weight gain as a risk factor for clinical diabetes mellitus in women, Ann Intern Med., 122, 481, 10.7326/0003-4819-122-7-199504010-00001 Carey, 1997, Body fat distribution and risk of non-insulin-dependent diabetes melli-tus in women. The Nurses' Health Study, Am J Epidemiol., 145, 614, 10.1093/oxfordjournals.aje.a009158 Rexrode, 1998, Abdominal adiposity and coronary heart disease in women, JAMA., 280, 1843, 10.1001/jama.280.21.1843 Dagenais, 2005, Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease, Am Heart J., 149, 54, 10.1016/j.ahj.2004.07.009 Calabrò, 2008, The role of adiposity as a determinant of an inflammatory milieu, J Cardiovasc Med (Hagerstown)., 9, 450, 10.2459/JCM.0b013e3282eee9a8 Qureshi, 2007, Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease, World J Gastroenterol., 13, 3540, 10.3748/wjg.v13.i26.3540 Lebovitz, 1999, Type 2 diabetes: An overview, Clin Chem., 45, 1339, 10.1093/clinchem/45.8.1339 Banerji, 1997, Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects, Am J Physiol., 273, E425 Després, 2008, Abdominal obesity and the metabolic syndrome: Contribution to global cardiometabolic risk [published correction appears in Arterioscler Thromb Vasc Biol. 2008;28:e151], Arterioscler Thromb Vasc Biol., 28, 1039 Eckel, 2005, The metabolic syndrome, Lancet., 365, 1415, 10.1016/S0140-6736(05)66378-7 Kahn, 2000, Obesity and insulin resistance, J Clin Invest., 106, 473, 10.1172/JCI10842 Jensen, 1989, Insulin regulation of lipolysis in nondiabetic and IDDM subjects, Diabetes., 38, 1595, 10.2337/diabetes.38.12.1595 Schindler, 2007, The metabolic syndrome as an endocrine disease: Is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?, Ther Adv Cardiovasc Dis., 1, 7, 10.1177/1753944707082662 Carr, 2004, Abdominal obesity and dyslipi-demia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk, J Clin Endocrinol Metab., 89, 2601, 10.1210/jc.2004-0432 Ginsberg, 2005, Regulation of plasma triglycerides in insulin resistance and diabetes, Arch Med Res., 36, 232, 10.1016/j.arcmed.2005.01.005 Barnett, 2008, The importance of treating cardiometabolic risk factors in patients with type 2 diabetes, Diab Vasc Dis Res., 5, 9, 10.3132/dvdr.2008.002 Weisberg, 2003, Obesity is associated with macrophage accumulation in adipose tissue, J Clin Invest., 112, 1796, 10.1172/JCI200319246 Fried, 1998, Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by gluco-corticoid, J Clin Endocrinol Metab., 83, 847, 10.1210/jc.83.3.847 Hotamisligil, 1996, IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance, Science., 271, 665, 10.1126/science.271.5249.665 Hotamisligil, 1993, Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance, Science., 259, 87, 10.1126/science.7678183 Feingold, 1992, Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis, Endocrinology, 130, 10, 10.1210/en.130.1.10 Lau, 2005, Adipokines: Molecular links between obesity and atherosclerosis, Am J Physiol Heart Circ Physiol., 288, H2031, 10.1152/ajpheart.01058.2004 Ouchi, 1999, Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin, Circulation., 100, 2473, 10.1161/01.CIR.100.25.2473 Nishimura, 2008, In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue, J Clin Invest., 118, 710 Fan, 2003, Inflammatory reactions in the pa-thogenesis of atherosclerosis, J Atheroscler Thromb., 10, 63, 10.5551/jat.10.63 Bastard, 2006, Recent advances in the relationship between obesity, inflammation, and insulin resistance, Eur Cytokine Netw., 17, 4 Ridker, 2000, Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men, Circulation., 101, 1767, 10.1161/01.CIR.101.15.1767 Kern, 2001, Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance, Am J Physiol Endocrinol Metab., 280, E745, 10.1152/ajpendo.2001.280.5.E745 Senn, 2002, Interleukin-6 induces cellular insulin resistance in hepatocytes, Diabetes, 51, 3391, 10.2337/diabetes.51.12.3391 Spranger, 2003, Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study, Diabetes, 52, 812, 10.2337/diabetes.52.3.812 Yamauchi, 2002, Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, Nat Med., 8, 1288, 10.1038/nm788 Kadowaki, 2005, Adiponectin and adiponectin receptors, Endocr Rev., 26, 439, 10.1210/er.2005-0005 Arita, 1999, Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity, Biochem Biophys Res Commun, 257, 79, 10.1006/bbrc.1999.0255 Ahima, 2006, Adipose tissue as an endocrine organ, Obesity (Silver Springs), 14, 242S, 10.1038/oby.2006.317 Maeda, 2001, PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein, Diabetes, 50, 2094, 10.2337/diabetes.50.9.2094 Bruun, 2003, Regulation of adi-ponectin by adipose tissue-derived cytokines: In vivo and in vitro investigations in humans, Am J Physiol Endocrinol Metab, 285, E527, 10.1152/ajpendo.00110.2003 Tilg, 2008, Inflammatory mechanisms in the regulation of insulin resistance, Mol Med., 14, 222, 10.2119/2007-00119.Tilg Okamoto, 2002, Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice, Circulation, 106, 2767, 10.1161/01.CIR.0000042707.50032.19 Ouchi, 2001, Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages, Circulation, 103, 1057, 10.1161/01.CIR.103.8.1057 Ouchi, 2000, Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway, Circulation, 102, 1296, 10.1161/01.CIR.102.11.1296 Pischon, 2004, Plasma adiponectin levels and risk of myocardial infarction in men, JAMA., 291, 1730, 10.1001/jama.291.14.1730 Ahima, 2000, Leptin, Annu Rev Physiol, 62, 413, 10.1146/annurev.physiol.62.1.413 Lefebvre, 1998, Depot-specific differences in adipose tissue gene expression in lean and obese subjects, Diabetes, 47, 98, 10.2337/diabetes.47.1.98 Leshan, 2006, Leptin receptor signaling and action in the central nervous system, Obesity (Silver Springs), 14, 208S, 10.1038/oby.2006.310 Déspres, 2008, From individual risk factors and the metabolic syndrome to global metabolic risk, Eur Heart J Suppl, 10, B24, 10.1093/eurheartj/sum041 Minokoshi, 2002, Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase, Nature, 415, 339, 10.1038/415339a Kamohara, 1997, Acute stimulation of glucose metabolism in mice by leptin treatment, Nature, 389, 374, 10.1038/38717 Cooke, 2002, Does leptin cause vascular disease?, Circulation, 106, 1904, 10.1161/01.CIR.0000036864.14101.1B Steppan, 2001, The hormone resis-tin links obesity to diabetes, Nature, 409, 307, 10.1038/35053000 Kusminski, 2005, Role of resistin in obesity, insulin resistance and Type II diabetes, Clin Sci (Lond), 109, 243, 10.1042/CS20050078 Verma, 2003, Resistin promotes endothelial cell activation: Further evidence of adipokine-endothelial interaction [published correction appears in Circulation. 2004;109:2254], Circulation, 108, 736, 10.1161/01.CIR.0000084503.91330.49 Loskutoff, 1998, The adipocyte and hemostatic balance in obesity: Studies of PAI-1, Arterioscler Thromb Vasc Biol, 18, 1, 10.1161/01.ATV.18.1.1 Juhan-Vague, 1997, PAI-1, obesity, insulin resistance and risk of cardiovascular events, Thromb Haemost, 78, 656, 10.1055/s-0038-1657607 Kohler, 2000, Plasminogen-activator inhibitor type 1 and coronary artery disease, N Engl J Med., 342, 1792, 10.1056/NEJM200006153422406 Lyon, 2003, Minireview: Adiposity, inflammation, and atherogenesis, Endocrinology, 144, 2195, 10.1210/en.2003-0285 Juhan-Vague, 1996, Thrombogenic and fibrinolytic factors and cardiovascular risk in non- insulin-dependent diabetes mellitus, Ann Med., 28, 371, 10.3109/07853899608999095 Kushner, 2003, Assessment of the obese patient, Endocrinol Metab Clin North Am., 32, 915, 10.1016/S0889-8529(03)00068-9 Stafford, 2000, National patterns of physician activities related to obesity management, Arch Fam Med., 9, 631, 10.1001/archfami.9.7.631 Bardia, 2007, Diagnosis of obesity by primary care physicians and impact on obesity management, Mayo Clin Proc., 82, 927, 10.4065/82.8.927 Klein, 2007, Diabetes Care., 30, 1647, 10.2337/dc07-9921 Pi-Sunyer, 2007, Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the Look AHEAD trial, Diabetes Care., 30, 1374, 10.2337/dc07-0048